Stay updated with breaking news from Rna Technology Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HONG KONG SAR - Media OutReach Newswire - 28 March 2024 - AIM Vaccine Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to
LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.
20 jul 2021 Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the res...
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines July 19, 2021 20:41 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-grow...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating ... Junshi BiosciencesJuly 20, 2021 GMT SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the proce...